No Data
No Data
No Data
Earnings Tell The Story For KPC Pharmaceuticals,Inc (SHSE:600422)
KPC Pharmaceuticals,Inc's (SHSE:600422) price-to-earnings (or "P/E") ratio of 36.6x might make it look like a sell right now compared to the market in China, where around half of the companies have P
China Resources Pharmaceutical (03320.HK): KPC achieved total revenue of 1,853 billion yuan in the first quarter
Gelonghui, April 22 | China Resources Pharmaceutical (03320.HK) announced that in the first quarter of 2024, KPC achieved total operating revenue of 1,853 billion yuan, a decrease of 3% year on year; net profit of 121 million yuan, a decrease of 10% year on year.
Kunming Pharmaceutical Group (600422): Steady improvement in business quality, non-growth in line with expectations
Core view In 2024, the company achieved operating income, net profit attributable to mother, and net profit after deduction of 1,853 million yuan, 119 million yuan, and 113 million yuan respectively, with year-on-year increases of -3.01% and -9.41 million yuan, respectively.
Kunming Pharmaceutical Group (600422): Local fine-tuning is expected to be lower and higher throughout the year
1Q24 deducted non-profit increased 9%. The company announced 1Q24 revenue of 1.85 billion yuan, net profit to mother of 120 million yuan, and deducted non-net profit of 110 million yuan, with year-on-year changes of -3%, -9%, and 9%. The decline in revenue was mainly due to foreign aid
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the thre
Dongwu Securities released a research report on April 21 stating that it gave KPC Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) the “Kunming Traditional Chinese Medicine 1381” brand has seen initial results, and the three major gold products have performed brilliantly; 2) the “777” brand was officially launched, and the high-quality development of the entire 37 industry chain continues to advance. (Mainichi Keizai Shimbun)
Kunming Pharmaceutical Group (600422): The “Kunming Traditional Chinese Medicine 1381” brand achieved initial results, and the three major gold products performed brilliantly
Key investment events: The 24Q1 company achieved operating income of 1,853 billion yuan (-3.01%, same ratio, same below), realized net profit to mother 119 million yuan (-9.41%), and achieved net profit of 1.13 billion yuan after deduction of non-return to mother
No Data